Loading...
Thumbnail Image
Item

UMB Begins Phase 3 of Novavax COVID-19 Vaccine Trial

Advisor
Date
2021-01-06
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
Article
Research Area
Jurisdiction
Other Titles
See at
Abstract
Data Availibility
Data / Code Location
Table of Contents
Description
News release from the UMB School of Medicine announcing the SOM's participation in a phase 3 clinical trial of a COVID-19 vaccine developed by biotechnology company, Novavax, Inc., based in Gaithersburg, MD.
Citations
Altmetric:
Series/Report No.
Sponsors
Rights/Terms
Identifier to cite or link to this item
Scopus Identifier
Embedded videos